Abstract

Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a major therapeutic goal. Historically, patients have been risk stratified on the basis of traditional factors, such as advanced age and thrombosis history. However, multiple factors contribute to the thrombotic tendency, including gender, mutational profile, inflammatory stress, and abnormal cell adhesion. Management includes cardiovascular risk reduction and use of antiplatelet therapy, depending on myeloproliferative neoplasm subtype and mutational status. Anticoagulation is a mainstay of therapy for those with venous thrombosis, but practice patterns remain heterogeneous. Cytoreduction is indicated for higher-risk patients, but efficacy may depend on the involved vascular bed. Management of special situations, such as unusual site thrombosis, bleeding, the perioperative period, and pregnancy, are especially challenging. In this article, risk factors and treatment strategies for myeloproliferative neoplasm thrombosis and bleeding, including special situations, are reviewed. Insights gained from recent studies may lead to the development of a more precise risk classification and tailored therapy.

References

References
1.
Rungjirajittranon
T
,
Owattanapanich
W
,
Ungprasert
P
,
Siritanaratkul
N
,
Ruchutrakool
T
.
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
.
BMC Cancer
.
2019
;
19
:
184
.
2.
Hultcrantz
M
,
Björkholm
M
,
Dickman
PW
, et al
.
Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study
.
Ann Intern Med
.
2018
;
168
(
5
):
317
-
325
.
3.
Finazzi
G
,
Carobbio
A
,
Thiele
J
, et al
.
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
.
Leukemia
.
2012
;
26
(
4
):
716
-
719
.
4.
Kaifie
A
,
Kirschner
M
,
Wolf
D
, et al
;
Study Alliance Leukemia (SAL)
.
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
.
J Hematol Oncol
.
2016
;
9
:
18
.
5.
Ferrari
A
,
Carobbio
A
,
Masciulli
A
, et al
.
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis [published online ahead of print 23 May 2019]
.
Haematologica
.
doi:10.3324/haematol.2019.221234
.
6.
Barbui
T
,
Finazzi
G
,
Carobbio
A
, et al
.
Development and validation of an International Prognostic Score of Thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
.
Blood
.
2012
;
120
(
26
):
5128
-
5133
,
quiz 5252
.
7.
Barbui
T
,
Vannucchi
AM
,
Buxhofer-Ausch
V
, et al
.
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
.
Blood Cancer J
.
2015
;
5
(
11
):
e369
.
8.
Haider
M
,
Gangat
N
,
Lasho
T
, et al
.
Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients
.
Am J Hematol
.
2016
;
91
(
4
):
390
-
394
.
9.
Sankar
K
,
Stein
BL
,
Rampal
R
.
Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms
. In: In:
Soff
G
, ed.
Thrombosis and Hemostasis in Cancer
.
Cancer Treatment and Research. Vol 179
.
Cham, Switzerland: Springer
;
2019
:
159
-
178
.
10.
Barbui
T
,
Vannucchi
AM
,
Carobbio
A
, et al
.
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
.
Am J Hematol
.
2017
;
92
(
1
):
E5
-
E6
.
11.
Horvat
I
,
Boban
A
,
Zadro
R
, et al
.
Influence of blood count, cardiovascular risks, inherited thrombophilia, and JAK2 V617F burden allele on type of thrombosis in patients with Philadelphia chromosome negative myeloproliferative neoplasms
.
Clin Lymphoma Myeloma Leuk
.
2019
;
19
(
1
):
53
-
63
.
12.
Marchioli
R
,
Finazzi
G
,
Specchia
G
, et al
;
CYTO-PV Collaborative Group
.
Cardiovascular events and intensity of treatment in polycythemia vera
.
N Engl J Med
.
2013
;
368
(
1
):
22
-
33
.
13.
Barbui
T
,
Masciulli
A
,
Marfisi
MR
, et al
.
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
.
Blood
.
2015
;
126
(
4
):
560
-
561
.
14.
Campbell
PJ
,
MacLean
C
,
Beer
PA
, et al
.
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
.
Blood
.
2012
;
120
(
7
):
1409
-
1411
.
15.
Carobbio
A
,
Ferrari
A
,
Masciulli
A
,
Ghirardi
A
,
Barosi
G
,
Barbui
T
.
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
.
Blood Adv
.
2019
;
3
(
11
):
1729
-
1737
.
16.
Barbui
T
,
Carobbio
A
,
Cervantes
F
, et al
.
Thrombosis in primary myelofibrosis: incidence and risk factors
.
Blood
.
2010
;
115
(
4
):
778
-
782
.
17.
Buxhofer-Ausch
V
,
Gisslinger
H
,
Thiele
J
, et al
.
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients
.
Am J Hematol
.
2012
;
87
(
7
):
669
-
672
.
18.
Rumi
E
,
Pietra
D
,
Ferretti
V
, et al
;
Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
.
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
.
Blood
.
2014
;
123
(
10
):
1544
-
1551
.
19.
Rotunno
G
,
Mannarelli
C
,
Guglielmelli
P
, et al
;
Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
.
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
.
Blood
.
2014
;
123
(
10
):
1552
-
1555
.
20.
Rumi
E
,
Pietra
D
,
Pascutto
C
, et al
;
Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
.
Blood
.
2014
;
124
(
7
):
1062
-
1069
.
21.
Vannucchi
AM
,
Antonioli
E
,
Guglielmelli
P
, et al
;
MPD Research Consortium
.
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
.
Leukemia
.
2007
;
21
(
9
):
1952
-
1959
.
22.
Tefferi
A
,
Lasho
TL
,
Guglielmelli
P
, et al
.
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
.
Blood Adv
.
2016
;
1
(
1
):
21
-
30
.
23.
Lussana
F
,
Carobbio
A
,
Salmoiraghi
S
, et al
.
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
.
J Hematol Oncol
.
2017
;
10
:
54
.
24.
Bar-Natan
M
,
Hoffman
R
.
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches
.
Haematologica
.
2019
;
104
(
1
):
3
-
6
.
25.
Guy
A
,
Gourdou-Latyszenok
V
,
Le Lay
N
, et al
.
Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
.
Haematologica
.
2019
;
104
(
1
):
70
-
81
.
26.
Guadall
A
,
Lesteven
E
,
Letort
G
, et al
.
Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features
.
Thromb Haemost
.
2018
;
118
(
9
):
1586
-
1599
.
27.
Ataga
KI
,
Kutlar
A
,
Kanter
J
, et al
.
Crizanlizumab for the prevention of pain crises in sickle cell disease
.
N Engl J Med
.
2017
;
376
(
5
):
429
-
439
.
28.
Edelmann
B
,
Gupta
N
,
Schnoeder
TM
, et al
.
JAK2-V617F promotes venous thrombosis through β12 integrin activation
.
J Clin Invest
.
2018
;
128
(
10
):
4359
-
4371
.
29.
Wolach
O
,
Sellar
RS
,
Martinod
K
, et al
.
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
.
Sci Transl Med
.
2018
;
10
(
436
):
eaan8292
.
30.
Wang
W
,
Liu
W
,
Fidler
T
, et al
.
Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2V617F mice
.
Circ Res
.
2018
;
123
(
11
):
e35
-
e47
.
31.
Landolfi
R
,
Marchioli
R
,
Kutti
J
, et al
;
European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
.
Efficacy and safety of low-dose aspirin in polycythemia vera
.
N Engl J Med
.
2004
;
350
(
2
):
114
-
124
.
32.
Chu
DK
,
Hillis
CM
,
Leong
DP
,
Anand
SS
,
Siegal
DM
.
Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review
.
Ann Intern Med
.
2017
;
167
(
3
):
170
-
180
.
33.
Alvarez-Larrán
A
,
Pereira
A
,
Guglielmelli
P
, et al
.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
.
Haematologica
.
2016
;
101
(
8
):
926
-
931
.
34.
De Stefano
V
,
Rocca
B
,
Tosetto
A
, et al
.
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
.
Blood Cancer J
.
2018
;
8
(
6
):
49
.
35.
Sankar
K
,
Stein
BL
.
Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction?
J Natl Compr Canc Netw
.
2018
;
16
(
12
):
1539
-
1545
.
36.
Godfrey
AL
,
Campbell
PJ
,
MacLean
C
, et al
;
United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; and the Australasian Leukaemia and Lymphoma Group
.
Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features
.
J Clin Oncol
.
2018
;
36
(
34
):
3361
-
3369
.
37.
Kander
EM
,
Moliterno
AR
,
Rademaker
A
,
Streiff
MB
,
Spivak
JL
,
Stein
BL
.
Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era
.
J Natl Compr Canc Netw
.
2016
;
14
(
10
):
1238
-
1245
.
38.
De Stefano
V
,
Rossi
E
,
Carobbio
A
, et al
.
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
.
Blood Cancer J
.
2018
;
8
(
11
):
112
.
39.
Mesa
RA
,
Jamieson
C
,
Bhatia
R
, et al
.
NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018
.
J Natl Compr Canc Netw
.
2017
;
15
(
10
):
1193
-
1207
.
40.
Barbui
T
,
Tefferi
A
,
Vannucchi
AM
, et al
.
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
.
Leukemia
.
2018
;
32
(
5
):
1057
-
1069
.
41.
Gisslinger
H
,
Gotic
M
,
Holowiecki
J
, et al
;
ANAHYDRET Study Group
.
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
.
Blood
.
2013
;
121
(
10
):
1720
-
1728
.
42.
Kiladjian
JJ
,
Zachée
P
,
Hino
M
, et al
.
Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (rux) with best available therapy (BAT) in hydroxyurea (HU)-resistant/intolerant patients (pts) with polycythemia vera (PV) [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
1753
.
43.
Carobbio
A
,
Finazzi
G
,
Antonioli
E
, et al
.
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
.
Blood
.
2010
;
116
(
7
):
1051
-
1055
.
44.
Hernández-Boluda
JC
,
Pereira
A
,
Cervantes
F
, et al
;
Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
.
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
.
Ann Hematol
.
2013
;
92
(
6
):
771
-
775
.
45.
Alvarez-Larrán
A
,
Pereira
A
,
Cervantes
F
, et al
.
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
.
Blood
.
2012
;
119
(
6
):
1363
-
1369
.
46.
Ellis
MH
,
Lavi
N
,
Vannucchi
A
,
Harrison
C
.
Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey
.
Thromb Res
.
2014
;
134
(
2
):
251
-
254
.
47.
Wille
K
,
Sadjadian
P
,
Becker
T
, et al
.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
.
Ann Hematol
.
2019
;
98
(
1
):
93
-
100
.
48.
Ianotto
JC
,
Couturier
MA
,
Galinat
H
, et al
.
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
.
Int J Hematol
.
2017
;
106
(
4
):
517
-
521
.
49.
NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines) for myeloproliferative neoplasms
,
version 2.2019. www.nccn.org. Accessed 24 June 2019
.
50.
Finazzi
G
,
Vannucchi
AM
,
Barbui
T
.
Prefibrotic myelofibrosis: treatment algorithm 2018
.
Blood Cancer J
.
2018
;
8
(
11
):
104
.
51.
Dentali
F
,
Ageno
W
,
Rumi
E
, et al
.
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases
.
Thromb Res
.
2014
;
134
(
1
):
41
-
43
.
52.
Akpan
IJ
,
Stein
BL
.
Splanchnic vein thrombosis in the myeloproliferative neoplasms
.
Curr Hematol Malig Rep
.
2018
;
13
(
3
):
183
-
190
.
53.
Smalberg
JH
,
Arends
LR
,
Valla
DC
,
Kiladjian
JJ
,
Janssen
HL
,
Leebeek
FW
.
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
.
Blood
.
2012
;
120
(
25
):
4921
-
4928
.
54.
Stein
BL
,
Saraf
S
,
Sobol
U
, et al
.
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
.
Leuk Lymphoma
.
2013
;
54
(
9
):
1989
-
1995
.
55.
How
J
,
Trinkaus
KM
,
Oh
ST
.
Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis
.
Br J Haematol
.
2018
;
183
(
2
):
310
-
313
.
56.
Li
M
,
De Stefano
V
,
Song
T
, et al
.
Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis
.
Thromb Res
.
2018
;
167
:
96
-
103
.
57.
Poisson
J
,
Plessier
A
,
Kiladjian
JJ
, et al
;
French National Network for Vascular Liver Diseases
.
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study
.
J Hepatol
.
2017
;
67
(
3
):
501
-
507
.
58.
Sozer
S
,
Fiel
MI
,
Schiano
T
,
Xu
M
,
Mascarenhas
J
,
Hoffman
R
.
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
.
Blood
.
2009
;
113
(
21
):
5246
-
5249
.
59.
Li
SL
,
Zhang
PJ
,
Sun
GX
,
Lu
ZJ
.
The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies
.
Ann Hematol
.
2014
;
93
(
11
):
1845
-
1852
.
60.
Colaizzo
D
,
Tiscia
GL
,
Bafunno
V
, et al
.
Sex modulation of the occurrence of JAK2 V617F mutation in patients with splanchnic venous thrombosis
.
Thromb Res
.
2011
;
128
(
3
):
233
-
236
.
61.
Finazzi
G
,
De Stefano
V
,
Barbui
T
.
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
.
Blood Cancer J
.
2018
;
8
(
7
):
64
.
62.
De Stefano
V
,
Vannucchi
AM
,
Ruggeri
M
, et al
.
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
.
Blood Cancer J
.
2016
;
6
(
11
):
e493
.
63.
Lavu
S
,
Szuber
N
,
Mudireddy
M
, et al
.
Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo Clinic experience with 84 consecutive cases
.
Am J Hematol
.
2018
;
93
(
3
):
E61
-
E64
.
64.
Pieri
L
,
Paoli
C
,
Arena
U
, et al
.
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
.
Am J Hematol
.
2017
;
92
(
2
):
187
-
195
.
65.
Reilly
CR
,
Babushok
DV
,
Martin
K
, et al
.
Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension
.
Am J Hematol
.
2017
;
92
(
9
):
909
-
914
.
66.
Potthoff
A
,
Attia
D
,
Pischke
S
, et al
.
Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms
.
Liver Int
.
2015
;
35
(
8
):
2042
-
2049
.
67.
Kander
EM
,
Raza
S
,
Zhou
Z
, et al
.
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
.
Int J Hematol
.
2015
;
102
(
5
):
587
-
593
.
68.
Marchioli
R
,
Finazzi
G
,
Landolfi
R
, et al
.
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
.
J Clin Oncol
.
2005
;
23
(
10
):
2224
-
2232
.
69.
Buss
DH
,
Stuart
JJ
,
Lipscomb
GE
.
The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases
.
Am J Hematol
.
1985
;
20
(
4
):
365
-
372
.
70.
Mital
A
,
Prejzner
W
,
Bieniaszewska
M
,
Hellmann
A
.
Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients
.
Pol Arch Med Wewn
.
2015
;
125
(
12
):
914
-
920
.
71.
Rottenstreich
A
,
Kleinstern
G
,
Krichevsky
S
,
Varon
D
,
Lavie
D
,
Kalish
Y
.
Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera
.
Eur J Intern Med
.
2017
;
41
:
49
-
54
.
72.
Bertozzi
I
,
Bogoni
G
,
Biagetti
G
, et al
.
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden
.
Ann Hematol
.
2017
;
96
(
8
):
1297
-
1302
.
73.
Borowczyk
M
,
Wojtaszewska
M
,
Lewandowski
K
, et al
.
The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms
.
Thromb Res
.
2015
;
135
(
2
):
272
-
280
.
74.
Harrison
CN
,
Campbell
PJ
,
Buck
G
, et al
;
United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
.
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
.
N Engl J Med
.
2005
;
353
(
1
):
33
-
45
.
75.
Birgegård
G
,
Besses
C
,
Griesshammer
M
, et al
.
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
.
Haematologica
.
2018
;
103
(
1
):
51
-
60
.
76.
Hernández-Boluda
JC
,
Arellano-Rodrigo
E
,
Cervantes
F
, et al
;
Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
.
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
.
Ann Hematol
.
2015
;
94
(
6
):
911
-
918
.
77.
De Stefano
V
,
Ruggeri
M
,
Cervantes
F
, et al
.
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
.
Leukemia
.
2016
;
30
(
10
):
2032
-
2038
.
78.
Appelmann
I
,
Kreher
S
,
Parmentier
S
, et al
.
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
.
Ann Hematol
.
2016
;
95
(
5
):
707
-
718
.
79.
Koren-Michowitz
M
,
Lavi
N
,
Ellis
MH
,
Vannucchi
AM
,
Mesa
R
,
Harrison
CN
.
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey
.
Ann Hematol
.
2017
;
96
(
1
):
87
-
92
.
80.
Ruggeri
M
,
Rodeghiero
F
,
Tosetto
A
, et al
;
Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Chronic Myeloproliferative Diseases Working Party
.
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
.
Blood
.
2008
;
111
(
2
):
666
-
671
.
81.
Alimam
S
,
Bewley
S
,
Chappell
LC
, et al
.
Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study
.
Br J Haematol
.
2016
;
175
(
1
):
31
-
36
.
82.
Lapoirie
J
,
Contis
A
,
Guy
A
, et al
.
Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms [published online ahead of print 26 June 2018]
.
J Matern Fetal Neonatal Med
.
doi:10.1080/14767058.2018.1484097
.
83.
Bertozzi
I
,
Rumi
E
,
Cavalloni
C
,
Cazzola
M
,
Fabris
F
,
Randi
ML
.
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera
.
Am J Hematol
.
2018
;
93
(
9
):
E234
-
E235
.
84.
McMullin
MFF
,
Mead
AJ
,
Ali
S
, et al
;
British Society for Haematology Guideline
.
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline
.
Br J Haematol
.
2019
;
184
(
2
):
161
-
175
.
85.
Skeith
L
,
Carrier
M
,
Robinson
SE
,
Alimam
S
,
Rodger
MA
.
Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis
.
Blood
.
2017
;
129
(
8
):
934
-
939
.
86.
Maze
D
,
Kazi
S
,
Gupta
V
, et al
.
Pregnancy outcomes in patients with myeloproliferative neoplasms: a systematic review and meta-analysis [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
3046
.
87.
Setiadi
H
,
Yago
T
,
Liu
Z
,
McEver
RP
.
Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis
.
Blood Adv
.
2019
;
3
(
2
):
168
-
183
.
88.
Stein
BL
,
Gerds
AT
.
Myeloproliferative neoplasms. In: Cuker A, Altman JK, Gerds AT, Wun T, eds. American Society of Hematology Self-Assessment Program
.
Washington, DC: American Society of Hematology;
2019
:
510
-
545
.
You do not currently have access to this content.